Pay-For-Delay Ban Heads To Full Senate

Law360, New York (July 21, 2011, 2:17 PM EDT) -- A bill designed to cut prescription drug costs by forcing pharmaceutical companies to show that any so-called pay-for-delay patent settlements are not anti-competitive narrowly advanced Thursday to the full U.S. Senate.

The Senate Judiciary Committee voted 10-8 along party lines to report the proposal to the full chamber. Similar bills — also proposed by Sen. Herb Kohl, D-Wis. — have moved out of the committee in previous Congresses but have failed to gain traction on the Senate floor.

"Generic drugs are often as much as 80...
To view the full article, register now.